
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Nucleus Network
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Study of BWC0977 Safety, Tolerability, & PK/PD in Healthy Adults
Details : BWC0977 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Communicable Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 19, 2025
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Nucleus Network
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BWC0977 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Communicable Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : The partnership between leading drug discovery start-up and leading cancer hospital paves way for the development of novel Immuno-oncology drugs that can be effective in wider patient populations.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 18, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BWC0977 is a highly potent, intravenous broad-spectrum antibiotic with the potential for oral administration, for the treatment of serious multi drug resistant (MDR) gram-negative infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2021
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BWC0977 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Communicable Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GYROX-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : University Of Tokyo Edge Capital
Deal Size : $7.5 million
Deal Type : Financing
Details : This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 22, 2020
Lead Product(s) : GYROX-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : University Of Tokyo Edge Capital
Deal Size : $7.5 million
Deal Type : Financing
